MyPRS Plus™ Testing
The MyPRS Plus™ testing methodology, published in Blood, gives peace of mind through result validity. MyPRS Plus is backed by over 10 years of research at the Myeloma Institute for Research and Therapy at the University of Arkansas Medical Sciences. By looking at the entire genome of the patient, Signal Genetics provides a predictive view of the patient’s prognosis, giving a basis for the best treatment plan for patients.
MyPRS Plus analyzes all of the nearly 25,000 genes in a patient’s genome to determine the gene expression profile (GEP) that is associated with their condition. In the case of myeloma, the GEP is made up of the 70 most relevant genes (GEP70) which aide in the prediction of the patient’s outcome. The gene expression profiling behind MyPRS Plus aides in efforts to offer truly personalized treatment options.